Assessment of drug–drug interaction potential with EDP‐305, a farnesoid X receptor agonist, in healthy subjects

EDP‐305 is a farnesoid X receptor (FXR) agonist that selectively activates FXR and is a potential treatment for patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis. Results from preclinical studies indicate that CYP3A4 is the primary enzyme involved in EDP‐305 metabolism and that E...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmad, Alaa, Adda, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468552/
https://www.ncbi.nlm.nih.gov/pubmed/35675500
http://dx.doi.org/10.1111/cts.13348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468552/
https://www.ncbi.nlm.nih.gov/pubmed/35675500
http://dx.doi.org/10.1111/cts.13348

Ejemplares similares